Search
for
Sort by
Research 901–930 of 1000+
- BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
- 1433 Epithelially derived, mitochondrial MPZL3 negatively regulates murine and human hair follicle cycling
- Chemical Danger in Hair Keratin Care
- Stem Cells Sheltered from Air-Raids Repair Airways
- Viewpoint 3
- SARS in Children
- Health hazard evaluation report: HETA-2000-0176-2829, The Centre for Well-Being at The Phoenician Resort, Scottsdale, Arizona.
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis
- Tofacitinib therapy for children with severe alopecia areata
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
- Response of alopecia areata of the beard to oral tofacitinib
- Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
- Baricitinib for the Treatment of Alopecia Areata
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus
- Adverse effects of baricitinib in comparison to methotrexate in the treatment of severe alopecia areata
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- EPH39 Alopecia Areata: Targeted Review of Adverse Events Associated with Clinical Studies of Treatments
- Anagen effluvium in extracorporeal membrane oxygenation
- Zinc in hair and urine of paediatric patients
- PREVALÊNCIA DE DISTÚRBIOS RESPIRATÓRIOS EM PACIENTES COM FISSURA LABIOPALATINA: REVISÃO SISTEMÁTICA
- Dynamic characteristics of cerebrovascular reactivity or ventilatory response to change in carbon dioxide